

ALTA US ALL CAP EQUITY FUND

November 2020

Fund Information Alta US All Cap Fund Name **Equity Fund** Alta Capital **Fund Manager** Management, LLC **Fund Inception** December 13, 2018 Share Class Inception December 13, 2018 Share Class **USD I Class** Growth/Quality Style Large, Mid, Small Cap Bottom-up Fundamental Legal Status **UCITS** Bloomberg **GCAUACI** IE00BHJWK831 ISIN Number of Holdings 30-35 Daily at NAV Liquidity Annual Management Fee 0.80% Minimum Investment \$500,000

Key Characteristics

Benchmark

- Robust cash flow generation
- Secular earnings growth with lower earnings per share variability

Russell 3000 Index

- Sustainable competitive advantages
- Profitability throughout the economic cycle
- Financial flexibility
- · Valuation consciousness

Fund Statistics

Top 10 Holdings

	Portfolio Weight %
Alphabet Inc.	6.6
Apple Inc.	5.7
Facebook, Inc.	4.9
Mastercard Inc.	4.3
Zebra Technologies Corp.	4.2
Thermo Fisher Scientific Inc.	3.8
NVIDIA Corp.	3.8
Booking Holdings Inc.	3.7
Fiserv, Inc.	3.7
Walt Disney Co.	3.5

Investment Objectives

The investment objective of the Fund is to seek long-term growth of capital by investing primarily in equity securities issued by high-quality companies listed on the New York Stock Exchange, the NASDAQ or the NYSE American.

Investment Process

- Companies are identified through a fundamental, bottomup investment process, beginning with a universe screen that seeks to identify quality companies that demonstrate financial strength, strong profitability, and a favorable track record.
- Further analysis of these firms using Alta's proprietary free cash flow model helps define the present value of the company. Fundamental analysis validates the strength of the company's management, business, and future performance expectations.
- The favorable culmination of this process is the recognition
 of a security whose current trading value is significantly
 less than its intrinsic value. To establish a position in a
 security, the Investment Committee must confirm eligibility,
 appropriate entry price target, and proper placement within
 the portfolio.

Portfolio Characteristics

	Fund	Benchmark
Number of Holdings	32	3,018
Dividend Yield	0.52	1.52
Market Cap (\$B)	309	384
Est 2 Yr EPS Growth	8.5	2.4
EPS Variability 5 Yr	46.0	45.4
Net Margin	14.5	5.7
Return on Invested Capital	13.7	2.8
Return on Equity	22.7	8.7
P/E NTM	28.5	23.0



ALTA US ALL CAP EQUITY FUND

November 2020

Manager Commentary

The leading performance contributors were Zebra Technologies Corporation, Booking Holdings Inc., and Ulta Beauty Inc. Zebra outperformed on the back of a beat and raise in Q3, driven by large order strength as the company continues to benefit from secular growth in e-commerce and the resulting investment in supply chains. While Booking's Q3 results underwhelmed expectations, the stock outperformed in November after a series of COVID-19 vaccine trial results showcased better than anticipated efficacy. This news increases confidence in the timeline for a return to pre-COVID levels of travel and hotel occupancy. This same vaccine news propelled shares of Ulta higher throughout the month, as a safe and expedited return to pre-COVID behavior should bode well for beauty spend and Ulta's physical store footprint.

Detractors were Thermo Fisher Scientific, Lowe's Companies, and Beckton, Dickinson and Co. Thermo fell in response to the COVID-19 vaccine news on fears that a successful vaccine will result in a sharp drop-off in COVID-19 testing. Testing products are still very much in demand and will likely remain so at least through 1H21. Lowe's shares dipped after the home improvement retailer saw sales come in strong across the board but lagged due to slightly weak guidance. The company's transformation strategy continues to provide ample opportunity for multiple and margin expansion. Becton's earnings results beat with conservative guidance, but the stock slipped on vaccine news, which could imply less COVID-19 testing revenues in 2021.

Contributors / Detractors 3rd Quarter


	Contribution to Portfolio Return %	
Zebra Technologies	0.76	
Booking Holdings Inc.	0.38	
Ulta Beauty Inc	0.47	
Thermo Fisher Scientific Inc.	-0.44	
Lowe's Companies, Inc.	-0.41	
Becton, Dickinson and Co.	-0.21	
	Booking Holdings Inc. Ulta Beauty Inc Thermo Fisher Scientific Inc. Lowe's Companies, Inc.	

Performance Analysis


	Fund %	Benchmark %	Relative Return %
3 Months	5.42	5.75	-0.32
YTD	17.06	15.68	1.37
1 Year	19.59	19.02	0.57
Since Inception*	22.93	20.16	2.77

^{*}Performance inception date December 14, 2018

Capitalization Breakdown



Sector Allocation



Health Care, 10.6%

Disclaimer: This document includes information concerning financial markets that was developed at a particular point in time and is subject to change at any time, without notice, and without update. This document may also include forward looking statements concerning anticipated results, circumstances, and expectations regarding future events. Forward-looking statements require assumptions to be made and are, therefore, subject to inherent risks and uncertainties. There is significant risk that predictions and other forward-looking statements will not prove to be accurate. Investing involves risk. Equity markets are volatile and will increase and decrease in response to economic, political, regulatory and other developments. Investment funds are not guaranteed, their values change frequently, and past performance is not a reliable indicator of future results. This information is for general information purposes only and is not intended as legal, tax, accounting, securities, or investment advice. This information is not intended for distribution into any jurisdiction where such distribution is restricted by law or regulation. It shall under no circumstances be considered an offer or solicitation to deal in any product mentioned herein. GuardCap Asset Management Limited is the promoter of the Fund while Alta Capital Management, LLC is the Manager of the Fund. For further information on this Fund please visit www.guardcap.co.uk to view the Prospectus, KIID and other relevant documents. This communication and any investment or service to which this material may relate does not constitute an offer or solicitation to invest in the Fund and is exclusively intended for persons who are Professional Clients or Eligible Counterparties for the purposes of the FCA Rules and other persons should not act or rely on it.